Skip to content


Entocort, Ortikos, Pulmicort, Rhinocort, Uceris, Jorveza (budesonide) is a small molecule pharmaceutical. Budesonide was first approved as Entocort on 1994-02-14. It is used to treat allergic rhinitis perennial and inflammatory bowel diseases in the USA. It has been approved in Europe to treat esophageal diseases. The pharmaceutical is active against glucocorticoid receptor. In addition, it is known to target progesterone receptor and mineralocorticoid receptor. Pulmicort respules's patents are valid until 2036-09-09 (FDA).
Trade Name Jorveza
Common Name Budesonide
Indication allergic rhinitis perennial, esophageal diseases, inflammatory bowel diseases
Drug Class Topical steroids (acetal derivatives)
Get full access now